Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer

Inclusion Criteria: * Female gender * 18 years or older * Performance Status- ECOG: 0-1 * Histologically confirmed invasive breast cancer * Primary tumor greater than 2 cm diameter * Any N (0-3) * No evidence of metastasis (M0), HER-2/ERBb2 negative. * Known hormone receptors status. * Haematopoietic status: Absolute neutrophil count \> 1.5 x 109/L; Platelet count \> 100 x 109/L * Hemoglobin at least 9 g/dl) * Hepatic status: Serum total bilirubin \< 1.5 x upper limit of normal (ULN), in the case of known Gilbert's syndrome, a higher serum total bilirubin (\< 2 x ULN) is allowed;AST and ALT \< 2.5 times ULN; Alkaline phosphatase \< 2.5 times ULN) * Renal status: Creatinine \< 1.5 mg/dl or Cl CR \> 60 ml/m * For women of childbearing potential Negative serum pregnancy test, within 2-weeks (preferably 7 days) prior to randomization. * Signed informed consent form (ICF). Exclusion Criteria: * Received any prior treatment for primary invasive breast cancer. * Previous (less than 10 years) or current history of malignant neoplasms, except for curatively treated: * Basal and squamous cell carcinoma of the skin;Carcinoma in situ of the cervix. * Diagnosis of inflammatory breast cancer. * Known history of uncontrolled or symptomatic angina, clinically significant arrhythmias, congestive heart failure, transmural myocardial infarction uncontrolled hypertension (? 180/110), unstable diabetes mellitus, dyspnoea at rest, or chronic therapy with oxygen. * Left Ventricular Ejection Fraction of \< 50% measured by echocardiography. * Concurrent disease or condition that would make the subject inappropriate for study participation or any serious medical disorder that would interfere with the subject?s safety. * Unresolved or unstable, serious adverse events from prior administration of another investigational drug. * Active or uncontrolled infection. * Dementia, altered mental status, or any psychiatric condition that would prevent the understanding or rendering of ICF. * Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy other than the trial therapies). * Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial. * Known immediate or delayed hypersensitivity reaction, idiosyncrasy or contraindication to drugs chemically related to any of the study treatments or their excipients. * Pregnant or lactating women. * Refusal to use contraception throughout the study (surgical sterilization, barrier methods associated with spermicidal gels or total abstinence). Use of hormonal contraceptives is not allowed. * Patient unable to comply with study procedures.